Oral medication study for moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 to 79 years old.
- You must have had atopic dermatitis (a type of eczema) for at least 12 months.
- Your eczema must be moderate to severe, meaning it covers a large area or is hard to control with topical creams.
- You must have used moisturizers daily for the week before the study starts.
- You should not have used certain strong eczema treatments (like oral steroids, immunosuppressants, or biologics) recently — check with the study team for the exact timeline.
- You must be willing to use reliable birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.